Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 5/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803242 | 0.85 | MAPT (0.31) | MAPT | |
| SCHEMBL14800530 | 0.85 | MAPT (0.31) | MAPT | |
| SCHEMBL14803005 | 0.85 | CYP3A4 (0.32) | OPRK1PIM1MAPT | |
| SCHEMBL14800662 | 0.85 | CYP3A4 (0.32) | OPRK1PIM1MAPT | |
| SCHEMBL14802971 | 0.85 | CYP3A4 (0.32) | OPRK1PIM1MAPT | |
| SCHEMBL14801683 | 0.84 | CYP2D6 (0.38) | PKMMAPT | |
| SCHEMBL27980111 | 0.83 | MAPT (0.30) | MAPT | |
| SCHEMBL14800944 | 0.82 | PIM1 (0.35) | PIM1 | |
| SCHEMBL14838546 | 0.82 | PIM1 (0.35) | PIM1 | |
| SCHEMBL14800733 | 0.82 | PIM1 (0.35) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| EP-3119775-B1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9931323-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3119775-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20170001997-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-9505746-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | GENENTECH, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9328106-B2 | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2015140189-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-24 | — | — | WO | disclosed |
| EP-2900657-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2760857-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8614206-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-24 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213652-A1 | Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use | PIM1, PIM2, PIM3 | OPRK1 1040/4885PKM 41/4885PIM1 1/4885 |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | OPRK1 757/4885PKM 8/4885PIM1 1/4885 |
| US-20170001997-A1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | OPRK1 98/4885PKM 40/4885PIM1 1/4885 |
| US-20140080801-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | OPRK1 757/4885PKM 8/4885PIM1 1/4885 |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | OPRK1 1040/4885PKM 41/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.